| Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. | |
| | |
MedLine Citation:
|
PMID: 20943777 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONTEXT AND OBJECTIVE: Strategies to augment pulsatile GH may be beneficial in patients with excess visceral adiposity, in whom GH secretion is reduced. The objective of this study was to determine the effects of a novel GHRH (GHRH(1-44)) analog, tesamorelin, on endogenous GH pulsatility and insulin sensitivity in healthy men. DESIGN, PARTICIPANTS, AND INTERVENTION: Thirteen males (mean age 45 ± 3 yr and body mass index 27.3 ± 1.2 kg/m(2)) received tesamorelin 2 mg sc once daily for 2 wk, with assessment made at baseline, after 2 wk of treatment, and after 2 wk of withdrawal. OUTCOME MEASURES: The primary end point was change in mean overnight GH as determined by overnight frequent sampling. Secondary end points included insulin-stimulated glucose uptake as measured by euglycemic hyperinsulinemic clamp; IGF-I; and GH secretion parameters, including pulse area, pulse frequency, and basal secretion. RESULTS: Tesamorelin treatment increased mean overnight GH (change +0.5 ± 0.1 μg/liter, P = 0.004), average log(10) GH peak area (change +0.4 ± 0.1 log(10) μg/liter, P = 0.001), and basal GH secretion (change +0.008 ± 0.003 μg/liter · min, P = 0.008). IGF-I increased by 181 ± 22 μg/liter (P < 0.0001). Neither fasting glucose (P = 0.93) nor insulin-stimulated glucose uptake (P = 0.61) was significantly affected by tesamorelin. CONCLUSIONS: Once-daily short-term treatment with a GHRH(1-44) analog, tesamorelin, augments basal and pulsatile GH secretion. Moreover, although tesamorelin significantly increases IGF-I, peripheral insulin-stimulated glucose uptake appears to be preserved. |
| | |
Authors:
|
Takara L Stanley; Cindy Y Chen; Karen L Branch; Hideo Makimura; Steven K Grinspoon |
Related Documents
:
|
19577077 - Increased vascular permeability after cardiopulmonary bypass in patients with diabetes ... 9379257 - Age-related decline in chondrocyte response to insulin-like growth factor-i: the role o... 6714337 - Abnormal marrow fibroblasts in aplastic anemia. 16444187 - The role of growth hormone in the pathogenesis of diabetic kidney disease. 9439557 - Australian diabetes screening study: impaired glucose tolerance and non-insulin-depende... 9771977 - A monoclonal antibody-based characterization of autoantibodies against glutamic acid de... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural Date: 2010-10-13 |
Journal Detail:
|
Title: The Journal of clinical endocrinology and metabolism Volume: 96 ISSN: 1945-7197 ISO Abbreviation: J. Clin. Endocrinol. Metab. Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2011-01-06 Completed Date: 2011-02-04 Revised Date: 2012-05-04 |
Medline Journal Info:
|
Nlm Unique ID: 0375362 Medline TA: J Clin Endocrinol Metab Country: United States |
Other Details:
|
Languages: eng Pagination: 150-8 Citation Subset: AIM; IM |
Affiliation:
|
Massachusetts General Hospital Program in Nutritional Metabolism, Harvard Medical School, Boston, Massachusetts 02114, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Blood Glucose / metabolism* Glucose Clamp Technique Growth Hormone-Releasing Hormone / analogs & derivatives*, pharmacology Human Growth Hormone / blood* Humans Insulin / pharmacology* Insulin-Like Growth Factor I / metabolism Male Middle Aged Pituitary Gland / drug effects* |
| Grant Support | |
ID/Acronym/Agency:
|
1 UL1 RR025758-01/RR/NCRR NIH HHS; F32 DK080642-02/DK/NIDDK NIH HHS; K23 DK087857-02/DK/NIDDK NIH HHS; K23 DK089910-01/DK/NIDDK NIH HHS; K23 DK089910-01/DK/NIDDK NIH HHS; K23 DK089910-02/DK/NIDDK NIH HHS; K23 DK089910-03/DK/NIDDK NIH HHS; K24 DK064545-08/DK/NIDDK NIH HHS; K24 DK064545-09/DK/NIDDK NIH HHS; M01-RR-01066/RR/NCRR NIH HHS; P30 DK040561-15/DK/NIDDK NIH HHS; R01 DK063639/DK/NIDDK NIH HHS; R01 DK063639-09/DK/NIDDK NIH HHS; R01DK063639/DK/NIDDK NIH HHS; T32 HD052961-03/HD/NICHD NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Insulin; 0/tesamorelin; 12629-01-5/Human Growth Hormone; 67763-96-6/Insulin-Like Growth Factor I; 9034-39-3/Growth Hormone-Releasing Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The human aldose reductase AKR1B1 qualifies as the primary prostaglandin F synthase in the endometri...
Next Document: Autosomal recessive mental retardation, deafness, ankylosis, and mild hypophosphatemia associated wi...